Health Care • Biotechnology: Pharmaceutical Preparations
$39.14 ▲ +0.85
(+2.22%)
MKT CAP: $173.31B • VOL: 10.44M
52W L $35 52W H $64
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$33
MEDIAN
$44
MEAN
$45
HIGH
$53
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE NVO TAPE
NVO // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $47.36 | $45.01 | 2025-02-14 | $35.62 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $49.32 | $46.19 | 2025-02-06 | $36.79 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $44.62 | $43.05 | 2025-01-29 | $37.57 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $39.92 | — | 2025-01-17 | $38.36 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $34.44 | $37.18 | 2025-01-09 | $34.83 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $46.58 | $40.71 | 2024-12-18 | $34.05 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $37.97 | $39.53 | 2024-12-04 | $36.40 | -4.3% | 48% | C |